COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Synairgen plc
Topline data from the ACTIV-2 Phase 2 study in home-based participants with COVID-19 showed that fewer participants required hospitalization following treatment with SNG001 compared to placebo- reported on Oct.4, 2022.

Phase 3 SPRINTER study of SNG001 did not meet the primary endpoints of discharge from hospital and recovery- reported on 21 February 2022.
Entos Pharmaceuticals
Covigenix VAX-001-1b- Covid-19 Vaccine candidate
Enrollment into Phase 2 study of Covigenix VAX-001-1b completed- reported on Sep.29, 2022.
ResVerlogix Corp.
Resverlogix's investigation of apabetalone to now focus on treatment of long-Covid instead of Covid-19 treatment- reported on September 28, 2022.
BerGenBio ASA
First patient has been included in a Phase 2b study of bemcentinib, as part of the EU-SolidAct trial in hospitalized COVID-19 patients- reported on Sept. 27, 2022
RVAC Medicines Pte. Ltd.
RVM-V001- mRNA COVID-19 vaccine candidate
Phase 1 study of RVM-V001 was initiated- reported on Sep.21, 2022.
Moat Biotechnology Corporation
Intranasal COVID-19 vaccine
Results from the phase 1 study showed that intranasal Covid-19 vaccine was safe and well tolerated in the initial ascending dose cohorts. In addition, a booster dose of the vaccine induced strong neutralizing antibody responses- reported on Sept. 20, 2022.
Omeros Corp.
Results from the narsoplimab arm of the I-SPY COVID Trial showed that addition of narsoplimab to treatment of critically ill patients with COVID-19 reduced the mortality risk. Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID trial- reported on Sept.15, 2022.
Quantum Leap Healthcare Collaborative
Phase 2 study evaluating PBI-0451 for the treatment and prevention of SARS-CoV-2 infections was initialed- reported on Sept. 13, 2022.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Ford Motor is increasing the entry-level price of its electric F-150 Lightning pickup citing rising costs and supply chain issues amid increasing demand. This is the second price hike after a recent increase in August. The starting price of the 2023 model year pickup will be raised by $5,000 by October 24, reports said citing an email statement. Constellation Brands, Inc. (STZ) said it delivered another quarter of strong business performance. Beer Business achieved double-digit net sales growth for the quarter, while Wine and Spirits net sales rose 1%. The solid top-line performance of its Beer and Wine and Spirits Businesses in the first half... Tyson Foods announced its "OneTyson" plan, under which it will bring together corporate team members from three corporate locations in Illinois and South Dakota to its world headquarters in Arkansas. Team members from the corporate locations of Chicago, Downers Grove in Illinois, and Dakota Dunes area in South Dakota are expected to begin the phased relocation in early 2023 to Springdale.